Riskpilot← Back to searchSign inGet full accessAJ Vaccines A/S
A/SActiveCVR 37911143Artillerivej 5Manufacture of pharmaceutical preparations · NACE 2120Est. 2016494 employees
Revenue 2024
DKK 413M
-12% vs 2023
EBITDA margin
-185.6%
-261% vs 2023
Equity ratio
46.1%
Financial strength
Net profit 2024
DKK -807,1M
-232% vs 2023
| Revenue | DKK 413M | -12% |
| EBITDA | DKK -766,3M | -261% |
| Net profit | DKK -807,1M | -232% |
| Total assets | DKK 1,1B | -31% |
| Equity | DKK 501,9M | -51% |
| Employees | 494 | — |
Legal name
AJ Vaccines A/S
CVR number
37911143
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
4. august 2016
Share capital
DKK 90.051.565
Employees
494 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af tre bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive virksomhed med udvikling, produktion og handel til indenlandske og udenlandske kunder af vacciner og andre biologiske lægemidler samt anden virksomhed, der efter bestyrelsens skøn er forbundet dermed.
Address
Artillerivej 5
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 351.618 | 351.862 | 420.982 | 468.886 | 412.969 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -433.564 | -455.058 | -226.829 | -212.229 | -766.299 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -433.564 | -455.058 | -226.829 | -212.229 | -766.299 |
| Net financials | -33.170 | -43.051 | -45.846 | -35.374 | -41.073 |
| Profit before tax | -452.537 | -488.398 | -268.810 | -242.923 | -807.117 |
| Tax | -2.325 | -2.010 | -721 | 51 | -0 |
| Net profit | -450.212 | -486.388 | -268.090 | -242.974 | -807.117 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1.727.645 | 1.472.466 | 1.534.005 | 1.587.337 | 1.088.929 |
| Equity | 1.052.358 | 815.875 | 994.663 | 1.020.362 | 501.919 |
| Long-term debt | 318.293 | 283.456 | 258.373 | 326.662 | 311.485 |
| Short-term debt | 356.994 | 373.135 | 280.970 | 240.313 | 275.525 |
| Total debt | 675.287 | 656.591 | 539.343 | 566.975 | 587.010 |
EBITDA margin
-185.6%
This company
15.8%
Market median
-1275% vs market
20202024
Equity ratio
46.1%
This company
38.2%
Market median
+21% vs market
20202024
Return on equity
-160.8%
This company
18.4%
Market median
-974% vs market
20202024
Net profit margin
-195.4%
This company
8.1%
Market median
-2512% vs market
20202024
Asset turnover
0.38×
This company
1.12×
Market median
-66% vs market
20202024
Debt / equity
1.17×
This company
0.62×
Market median
-89% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
OV Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (6) | ||
JH Chief Executive Officer | Chief Executive Officer | 2018 – 2022 |
HJ Chief Executive Officer | Chief Executive Officer | 2016 – 2016 |
JC Management | Management | 2019 – 2021 |
PB Management | Management | 2016 – 2017 |
KH Chief Executive Officer | Chief Executive Officer | 2017 – 2018 |
JC Management | Management | 2019 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2017 | |
| Chairman | 2023 | |
| Board of Directors | 2020 | |
| Board of Directors | 2024 | |
| Board of Directors | 2021 | |
| Former (9) | ||
| Board of Directors | 2016 – 2017 | |
| Chairman | 2017 – 2022 | |
| Board of Directors | 2018 – 2020 | |
| Chairman | 2016 – 2016 | |
| Chairman | 2016 – 2017 | |
| Board of Directors | 2016 – 2016 | |
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2022 – 2024 | |
| Chairman | 2022 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2017 | |
| Company | 100% | 100% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AJ Vaccines Holding ApS
AJ Vaccines A/S Board members of AJ Vaccines A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jesper Helmuth Larsen | Chief Executive Officer | 0 companies |
| Henrik Juul Hansen | Chief Executive Officer | 0 companies |
| Jérome Christian Roger Cabannes | Management | 0 companies |
| Pia Birgitte Lading | Management | 0 companies |
| Ole Vahlgren | Chief Executive Officer | 0 companies |
| Klaus Hermansen | Chief Executive Officer | 0 companies |
| Jerome Christian Roger Cabannes | Management | 0 companies |
| Mie Lund Buhl | Board of Directors | 0 companies |
| Tabassum Khan | Chairman | 0 companies |
| Saddam Abdulqawi Hussein Alhumaikani | Board of Directors | 0 companies |
| Mustafa Nasir Farooki | Board of Directors | 0 companies |
| Abdulaziz Abdulhamid Abdulrhman Albassam | Chairman | 0 companies |
| Ivan Madsen | Chairman | 0 companies |
| Helle Birk Krogsgaard | Chairman | 0 companies |
| Poul Jagd Mogensen | Board of Directors | 0 companies |
| Saddam Abdulqawi Hussein Alhumaikani | Board of Directors | 0 companies |
| Abdul Wahab Mohammed A Alesayi | Board of Directors | 0 companies |
| Tarek Sherif Ahmed Abbas Hegazy | Board of Directors | 0 companies |
| Shan-E-Abbas Ashary | Board of Directors | 0 companies |
| Mohammed Ali A Alesayi | Board of Directors | 0 companies |
| Abdulaziz Hamad Aljomaih | Chairman | 0 companies |